Natalie Ward

Dr. Natalie Ward is currently a Director within the Global Regulatory Sciences - CMC, Cell Therapy team at BMS. Here, she is the Regulatory CMC lead on arlocabtagene autoleucel (arlo-cel); a late-stage GPRC5D-directed CAR-T product. Natalie has 20 years’ experience in development of cell and gene therapy (CGT) products with R&D experience gained during her PhD and postdoctoral posts, and CMC development experience at GSK where she worked on the late-stage development of autologous ex vivo gene therapy products, including STRIMVELIS. Prior to joining BMS Natalie worked within the Regulatory CMC teams at the UK Cell and Gene Therapy Catapult and BioMarin supporting early CGT development programs, and Adaptimmune where she supported the late-stage development and registration of TECELRA (afamitresgene autoleucel), the first FDA-approved T cell receptor (TCR) gene therapy. Natalie’s current interests include understanding the CMC challenges experienced for CGT and other complex products and how these can be mitigated.